TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21467190
Drug: Methylphenidate (30
Normalized name: methylphenidate (30/70 release) 10 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (30 and 60 mg)
Study: 15153211
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 microg.kg(‐1)) added to bupivacaine (1 mg.kg(‐1) 0.125%)
Study: 15153211
Drug: Saline added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline added to bupivacaine (1 mg.kg(‐1) 0.125%)
Study: 11444468
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of colloidal bismuth subcitrate and metronidazole or omeprazole, clarithromycin and amoxycillin for H. pylori eradication
Study: 11444468
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate for anaemia treatment
Study: 9765010
Drug: Fluconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (50 mg/day for 7 days)
Study: 9765010
Drug: Nystatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (1 mL 4 times a day for 21 days)
Study: 7824094
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) treatment as mono-therapy (n = 36) or polytherapy (n = 16) with a mean dosage of 17 mg/kg body weight.
Study: 7824094
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) treatment in polytherapy (n = 16).
Study: 7824094
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) treatment as a nonretarded formulation.
Study: 7824094
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) treatment.
Study: 3385554
Drug: Glycine-fortified ORS
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine-fortified ORS (55 or 110 mmol/L glycine)
Study: 31343447
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available comparator gels
Study: 15874923
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg twice daily, supplemented by intravenous doses when necessary)
Study: 28621820
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (ICBT)
Study: 28468739
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance (25 mg po for 21 days)
Study: 26125454
Drug: Local incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local incision warming (6 post-operative treatments)
Study: 18385963
Drug: Empiric studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empiric studies concerning the treatment of depressive disorders in children and adolescents; specific interventions not detailed.
Study: 8922764
Drug: Droperidol 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.04 mg.mg-1 of PCA morphine
Study: 8922764
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including droperidol 0.0 and 0.02 mg.mg-1 of PCA morphine)
Study: 3901661
Drug: Cholestyramine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 2 g twice daily
Study: 3901661
Drug: Loperamide 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 0.10 mg/kg divided in three doses
Study: 3901661
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 g twice daily
Study: 30142767
Drug: Socheongryong-tang (SCRT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Socheongryong-tang (SCRT) taken twice daily for 2 weeks
Study: 30142767
Drug: Cetirizine taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine taken once daily for 2 weeks
Study: 14558052
Drug: Intensive dynamic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dynamic exercise program (75 minutes, twice a week, for 2 years)
Study: 6749152
Drug: vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin K2 6 mg
Study: 6749152
Drug: vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin K2 2 mg
Study: 6749152
Drug: vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin K1 2 mg
Study: 24727030
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline solution instillation)
Study: 21815168
Drug: Dietary treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatments with fish oil and vegetable oils
Study: 10749457
Drug: Heptavalent CRM197
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent CRM197 pneumococcal conjugate vaccine
Study: 1302788
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose midazolam
Study: 2938871
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of alpha‐human atrial natriuretic peptide (alpha‐h‐ANP) at a dose of 15 pmol min‐1 kg‐1
Study: 2938871
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of alpha‐h‐ANP at a dose of 1.5 pmol min‐1 kg‐1
Study: 2938871
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of alpha‐h‐ANP
Study: 18031444
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading (6 weeks after implant placement)
Study: 18031444
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading (6 months after implant placement)
Study: 7733024
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg zinc supplement (ZS, n = 40)
Study: 30941440
Drug: Painful shocks
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful shocks administered after presentation of some words (pain condition)
Study: 30941440
Drug: No shocks
Approvals — FDA: no, EMA: no, PMDA: no
Description: No shocks administered (pain-free condition)
Study: 22088414
Drug: Branded etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Branded etanercept (25 mg)
Study: 22088414
Drug: Biosimilar etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biosimilar etanercept (25 mg)
Study: 17300242
Drug: ALA-PDT (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (20% ALA solution under occlusive dressing for 3 h followed by helium-neon laser irradiation at 100 J cm(‐2) and 100 mW power)
Study: 17300242
Drug: ALA-PDT (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (after two treatments)
Study: 17300242
Drug: Control (CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CO2 laser treatment)
Study: 9463202
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ketorolac
Study: 3555276
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of diclofenac
Study: 9059768
Drug: Insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetes mellitus (IDDM)
Study: 9059768
Drug: Non-insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-dependent diabetes mellitus (NIDDM)
Study: 2900816
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg of broxaterol hydrochloride
Study: 2900816
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg of broxaterol hydrochloride
Study: 2900816
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg of salbutamol
Study: 28431145
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine sulphate
Study: 24461666
Drug: Ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 150 mg twice daily
Study: 20684151
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microsphere (TGM) 0.04% pump
Study: 20684151
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% plus benzoyl peroxide 2.5% gel (ADA-BPO 0.1%/2.5%)
Study: 18064474
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg x 2 daily during radiation
Study: 18064474
Drug: Uracil-tegafur 300
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil-tegafur 300 mg/m2 daily during radiation
Study: 1611979
Drug: Ornipressin (POR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin (POR 8) at a standard concentration of 0.2 i.u./ml
Study: 1611979
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution (Control)
Study: 26975694
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (without psychoeducation)
Study: 18922613
Drug: Tooth Mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth Mousse (TM) applied for 60 min daily for 7 days; smear layer retained (group 1)
Study: 18922613
Drug: Tooth Mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth Mousse (TM) applied for 60 min daily for 7 days; smear layer removed (group 2)
Study: 18922613
Drug: Preconditioning with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconditioning with 20% polyacrylic acid (CC)
Study: 24654454
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) treatment
Study: 8669405
Drug: Ethanol (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (5% of total daily energy intake)
Study: 8669405
Drug: Carbohydrate (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (5% of total daily energy intake)
Study: 9151364
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg THIP
Study: 7963155
Drug: Prednisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.5 mg/kg/day)
Study: 23471817
Drug: Dosing cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing cup
Study: 18504547
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml white wine (approximately 25 g alcohol/day)
Study: 1373337
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of high-osmolarity ionic contrast medium
Study: 1373337
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of low-osmolarity non-ionic contrast medium
Study: 1373337
Drug: Lower fixed
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower fixed dose of low-osmolarity non-ionic contrast medium
Study: 31959346
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg twice daily
Study: 24297951
Drug: Intravenous calcium/magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium/magnesium before and after oxaliplatin
Study: 22323092
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) administered intravenously, titrated according to a weight-adjusted dosing nomogram to a target aPTT of 1.5-2 times the upper limit of normal (approximately 50-70 s), median treatment duration of 42 hours.
Study: 22323092
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) treatment with aPTT categorized as persistently below <50 s for recurrent ischemic events.
Study: 22323092
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) treatment with aPTT categorized as persistently above >70 s for major hemorrhagic events.
Study: 20196118
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Study: 20196118
Drug: 16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Study: 20196118
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of treatment in genotype 2
Study: 20196118
Drug: 16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks of treatment in genotype 2
Study: 20196118
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of treatment in genotype 3
Study: 20196118
Drug: 16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks of treatment in genotype 3
Study: 18613251
Drug: Novel combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel combination of models estimating hazard rate
Study: 14520130
Drug: Nefazodone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone and Fluoxetine
Study: 10919932
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acid‐enriched oil (supplement)
Study: 1364197
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg midazolam (n = 7)
Study: 1364197
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg vecuronium (n = 8)
Study: 12974184
Drug: saccharosum +
Normalized name: Acer saccharinum pollen
DrugBank: Acer saccharinum pollen (DB10735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: saccharosum + sennosid-B solution
Study: 28965122
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (7.20 mg ED50 for motor block)
Study: 28965122
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine (10.05 mg ED50 for motor block)
Study: 23208128
Drug: EGFR tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EGFR tyrosine kinase inhibitors (TKI)
Study: 23208128
Drug: Chemotherapy among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy among the three groups
Study: 10224735
Drug: 18 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 sessions of twice-weekly exposure therapy
Study: 10224735
Drug: 18 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 sessions of twice-weekly exposure therapy followed by 16 sessions of behavioral family therapy (BFT)
Study: 8630312
Drug: All oral
Normalized name: Exall Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All oral contraceptives studied
Study: 6356972
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl concentrations below 10 micrograms/ml
Study: 6356972
Drug: More dilute
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More dilute solutions of epidural fentanyl
Study: 27930447
Drug: Carbohydrate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate and caffeine (CHO-C) (40 g·h + 3 mg·kg)
Study: 27930447
Drug: Carbohydrate (CHO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO; 40 g·h)
Study: 24738883
Drug: Preservative-free fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free fixed combination (FC) of tafluprost 0.0015%/timolol 0.5%
Study: 24738883
Drug: Non-fixed combination
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fixed combination (NFC) of tafluprost 0.0015% and timolol 0.5%
Study: 1960551
Drug: IFN‐alpha 2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha 2A 20 x 10(6) U/m2 intramuscularly three times a week with ASA 600 mg orally four times daily
Study: 7014349
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucagon infusion (24 U regular insulin and 2.4 mg glucagon over 12 h daily for 3 weeks)
Study: 7014349
Drug: Dextrose solution
Normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose solution (200 ml over the same time period)
Study: 31500494
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment at 20 mmHg
Study: 28576350
Drug: Sativex Oromucosal
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex Oromucosal Spray (active group, n=15)
Study: 25538173
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus FOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, folinic acid 200 mg/m2, 5-fluorouracil 3200 mg/m2 every 2 weeks)
Study: 25538173
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus mFOLFOX-6 (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus then 2400 mg/m2 46-h infusion every 2 weeks)
Study: 23667876
Drug: Neuroprotector Cortexin
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotector Cortexin added to standard drug therapy
Study: 17505806
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (tizanidine, fluoxetine, vinpocetin, and manual acupressure)
Study: 12772723
Drug: New hyper-oxygen
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New hyper-oxygen transmissible lenses (daily and extended wear)
Study: 10761262
Drug: Maximal androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal androgen deprivation prior to and during definitive radiation therapy
Study: 1383434
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy RT (radiation therapy) after good response to chemotherapy
Study: 3315765
Drug: Intranasal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal human insulin 100 U/ml with sodium glycocholate 4 % w/v, administered as a spray solution (0.5 U/Kg b.w.)
Study: 3315765
Drug: Intranasal regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal regular porcine and human insulin 40 U/ml with sodium glycocholate 1 % w/v, administered in drops (0.9 U/Kg b.w.)
Study: 20353621
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT) with Motivational Interviewing (MI) and Thought Mapping (TM)
Study: 10868622
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy in CMV seronegative recipients
Study: 1442491
Drug: amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: amiodarone plus xamoterol (200 mg two times daily)
Study: 1442491
Drug: amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: amiodarone plus metoprolol (50 mg two times daily)
Study: 1442491
Drug: amiodarone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: amiodarone plus beta-blockers (metoprolol or xamoterol)
Study: 2857633
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (0.5 g t.i.d.)
Study: 2857633
Drug: salazosulfapyridine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: salazosulfapyridine (1.0 g t.i.d.)
Study: 18640933
Drug: mFOLFOX6 (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin)
Study: 18640933
Drug: bFOL (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFOL (bolus FU and low-dose LV with oxaliplatin)
Study: 16447879
Drug: Large dosage
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dosage of salvia injection (24 ml)
Study: 16447879
Drug: Middle dosage
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dosage of salvia injection (16 ml)
Study: 16447879
Drug: Small dosage
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dosage of salvia injection (8 ml)
Study: 16447879
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no salvia injection)
Study: 16447879
Drug: Overall efficacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall efficacy of salvia injection